eli lilly - Search News

News

Eli Lilly shares fall

Dow, S&P 500 end lower; Eli Lilly shares fall after drug data

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, while Nasdaq ended slightly higher.

Forbes on MSN · 3h

Eli Lilly Shares Plummet 14% Toward Worst Day In 25 Years—Here’s Why It’s Down

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or overweight patients without diabetes lose just over 12% of their body weight in a late-stage trial, behind analyst expectations of 15%, according to FactSet.

CNBC on MSN · 3h

Leerink's Risinger on Eli Lilly downgrade: Triggered by disappointing obesity pill results

David Risinger, Leerink Partners senior research analyst, joins 'Power Lunch' to discuss how competitive Eli Lilly's business is, what to expect by the end of the decade and much more.

Eli Lilly weight loss pill shows promise

Fast Company · 2h

Eli Lilly is giving Novo Nordisk a run for its money—so why is LLY stock still down today?

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors remain unconvinced.

MarketWatch on MSN · 5h

Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging

Lilly’s stock was tumbling as disappointing trial data for an oral weight-loss pill offset an upbeat earnings report and outlook.

CBS News on MSN · 5h

Eli Lilly weight loss pill shows promise in latest clinical trial

In a Phase 3 trial, drugmaker Eli Lilly and Company said it's oral GLP-1 pill showed similar results to injectable weight loss options after a 72-week period.

S&P 500 eases with Eli Lilly; Nasdaq manages record closing high

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

2hon MSN

Eli Lilly happy with weight loss pill performance as drugmaker races to be the first to market

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

11hon MSN

Experimental GLP-1 pill helped people with obesity lose weight, Eli Lilly says

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Stocks to Watch Thursday: Eli Lilly, Firefly, DoorDash, TSMC

The iPhone maker's shares [rallied for a second day]( ...

STAT1h

Closing a zombie biotech, and Lilly’s disappointing obesity readout

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Eli Lilly to sell troubled N.J. pharmaceutical plant, but says jobs are safe. Here’s why.

Eli Lilly and Company has confirmed it’s selling its 25,000-square-foot manufacturing site in Branchburg. The decision was ...

Eli Lilly beats earnings for second quarter on strong GLP-1 sales, stock dives on GLP-1 pill trial results

Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results